1. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. (2nd February 2018) Authors: Vokes, E E; Ready, N; Felip, E; Horn, L; Burgio, M A; Antonia, S J; Arén Frontera, O; Gettinger, S; Holgado, E; Spigel, D; Waterhouse, D; Domine, M; Garassino, M; Chow, L Q M; Blumenschein, G; Barlesi, F; Coudert, B; Gainor, J; Arrieta, O; Brahmer, J Journal: Annals of oncology Issue: Volume 29:Number 4(2018) Page Start: 959 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. LBA57Overall survival results of ceritinib in ALKi-naïve patients with ALK-rearranged NSCLC (ASCEND-3). (23rd October 2018) Authors: Felip, E; Nishio, M; Orlov, S; Park, K; Yu, C-J; Tsai, C-M; Cobo, M; McKeage, M; Su, W-C; SK Mok, T; Scagliotti, G V; Spigel, D; Passos, V Q; Chen, Z; Shaw, A T Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗